William D. Baird III Sells 10,000 Shares of Amicus Therapeutics, Inc. (FOLD) Stock

Share on StockTwits

Amicus Therapeutics, Inc. (NASDAQ:FOLD) CFO William D. Baird III sold 10,000 shares of Amicus Therapeutics stock in a transaction on Monday, July 2nd. The shares were sold at an average price of $15.63, for a total transaction of $156,300.00. Following the completion of the transaction, the chief financial officer now directly owns 117,622 shares in the company, valued at $1,838,431.86. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website.

Shares of Amicus Therapeutics opened at $16.13 on Friday, according to MarketBeat.com. The company has a debt-to-equity ratio of 0.32, a quick ratio of 4.15 and a current ratio of 4.21. Amicus Therapeutics, Inc. has a 1 year low of $10.18 and a 1 year high of $17.62.

Amicus Therapeutics (NASDAQ:FOLD) last announced its quarterly earnings data on Tuesday, May 8th. The biopharmaceutical company reported ($0.28) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.36) by $0.08. The company had revenue of $16.70 million for the quarter, compared to analysts’ expectations of $16.78 million. Amicus Therapeutics had a negative net margin of 563.98% and a negative return on equity of 60.09%. sell-side analysts anticipate that Amicus Therapeutics, Inc. will post -1.3 earnings per share for the current fiscal year.

A number of brokerages have recently commented on FOLD. BidaskClub raised shares of Amicus Therapeutics from a “hold” rating to a “buy” rating in a report on Friday, May 4th. Zacks Investment Research raised shares of Amicus Therapeutics from a “sell” rating to a “hold” rating in a report on Thursday, May 10th. Cowen reaffirmed a “buy” rating and issued a $22.00 target price on shares of Amicus Therapeutics in a report on Tuesday, May 8th. Finally, ValuEngine raised shares of Amicus Therapeutics from a “buy” rating to a “strong-buy” rating in a report on Wednesday, May 2nd. Three research analysts have rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the company. The stock presently has a consensus rating of “Buy” and an average target price of $19.06.

A number of institutional investors and hedge funds have recently made changes to their positions in FOLD. Lord Abbett & CO. LLC acquired a new position in Amicus Therapeutics in the 1st quarter valued at $22,662,000. BlackRock Inc. boosted its position in shares of Amicus Therapeutics by 10.1% during the 1st quarter. BlackRock Inc. now owns 15,090,252 shares of the biopharmaceutical company’s stock worth $226,957,000 after purchasing an additional 1,378,155 shares in the last quarter. Millennium Management LLC purchased a new stake in shares of Amicus Therapeutics during the 4th quarter worth $18,974,000. Sphera Funds Management LTD. boosted its position in shares of Amicus Therapeutics by 67.8% during the 1st quarter. Sphera Funds Management LTD. now owns 1,845,704 shares of the biopharmaceutical company’s stock worth $27,759,000 after purchasing an additional 745,704 shares in the last quarter. Finally, Redmile Group LLC boosted its position in shares of Amicus Therapeutics by 7.1% during the 1st quarter. Redmile Group LLC now owns 10,738,658 shares of the biopharmaceutical company’s stock worth $161,509,000 after purchasing an additional 712,888 shares in the last quarter.

About Amicus Therapeutics

Amicus Therapeutics, Inc, a biotechnology company, engages in the discovery, development, and commercialization of medicines for various rare and orphan diseases. The company offers migalastat HCl, an orally administered small molecule pharmacological chaperone for the treatment of Fabry disease. It is also conducting a Phase 1/2 clinical study of ATB200-02 to investigate in patients with pompe disease.

Insider Buying and Selling by Quarter for Amicus Therapeutics (NASDAQ:FOLD)

Receive News & Ratings for Amicus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amicus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply